Baxter International (BAX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
5 May, 2026Opening remarks and agenda
Meeting conducted via webcast for safety and convenience, with technical support available.
Agenda and matters to be considered were distributed to all stockholders.
Five items of business were scheduled for voting, with Q&A to follow if time permitted.
Board and executive committee updates
Board members introduced, including a new director, Mike McDonnell.
Retirements and resignations of Dr. Stephen Oesterle, Cathy Smith, and Stephen Rusckowski acknowledged.
Corporate governance
Quorum established with majority of 516 million shares represented.
Inspector of Elections and independent auditor present; auditor available for Q&A.
Voting procedures and proxy rules explained, with opportunity to change votes during the meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Baxter International
- Q1 2026 sales up 3% reported, adjusted EPS down 35%, full-year outlook reiterated.BAX
Q1 202630 Apr 2026 - Proposal to amend Board size parameters aims to enhance flexibility and governance.BAX
Proxy filing29 Apr 2026 - Q4 sales up 8% but adjusted EPS down 24%; 2026 outlook flat with margin recovery expected.BAX
Q4 202512 Apr 2026 - Shareholders will vote on key governance, compensation, and board structure changes, all recommended for approval.BAX
Proxy filing23 Mar 2026 - Shareholders to vote on director elections, executive pay, auditor, and board size changes.BAX
Proxy filing23 Mar 2026 - Proxy seeks approval for Board refreshment, pay practices, auditor, and sustainability focus.BAX
Proxy Filing13 Mar 2026 - Oil price exposure halved, new operating model boosts efficiency, and margin recovery expected.BAX
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Stable fundamentals, prudent 2026 outlook, and focus on innovation and deleveraging.BAX
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Q2 sales and adjusted EPS beat guidance; net loss from goodwill impairment; guidance raised.BAX
Q2 20242 Feb 2026